Related Experiment Video
Updated: Oct 3, 2025
Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse
Published on: July 25, 2025
Subconjunctival Rituximab Administration for the Treatment of Scleritis
D P C Vergouwen1,2, J C Ten Berge1, N C Naus-Postema1
1Department of Ophthalmology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Purpose:
Scleritis is a sight-threatening inflammation, which is commonly accompanied by severe complications. Aggressive systemic immunosuppressive treatment, which is frequently needed, can be associated with serious complications, and might therefore be (temporarily) contraindicated.
Methods:
We report on the outcomes of three patients with severe, active, non-infectious scleritis, refractory or intolerant to systemic treatment, who received subconjunctival rituximab (RTX) injections. A dose of 2.5 to 7.5 mg was administered after topical anesthesia, and follow-up varied from 8 to 10 months.
Results:
Subconjunctival RTX showed minimal to no effect on subjective symptoms, clinical features and/or ultrasound images. No serious adverse effects occurred.
Conclusion:
Further studies are needed to assess the effect of local administration of RTX in scleritis, but our limited observation is not promising.
More Related Videos
12:45Development of a Refined Protocol for Trans-scleral Subretinal Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes
Published on: August 12, 2017
12:25Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
Published on: January 6, 2018